Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice

• Shaohuan Lu ,

  Contributed equally to this work with: Shaohuan Lu, Dongxiao Wang

  Roles Conceptualization, Writing – original draft

  Affiliation Department of Pharmacy, The First People’s Hospital of Yulin, Yulin, Guangxi, China

  ⨯
• Dongxiao Wang ,

  Contributed equally to this work with: Shaohuan Lu, Dongxiao Wang

  Roles Conceptualization, Writing – original draft

  Affiliation Department of Pharmacy, Yulin Maternal and Child Health Hospital, Yulin, Guangxi, China

  ⨯
• Caiming Xiong,

  Roles Data curation, Investigation

  Affiliation School of Pharmacy, Guangxi Medical University, Nanning, Guangxi, China

  ⨯
• Jialing Liang,

  Roles Investigation

  Affiliation Yulin Campus, Guangxi Medical University, Yulin, Guangxi, China

  ⨯
• Yang Li,

  Roles Visualization

  Affiliation Department of Pharmacy, The First People’s Hospital of Yulin, Yulin, Guangxi, China

  ⨯
• Canhua Liang,

  Roles Data curation

  Affiliation Department of Pharmacy, The First People’s Hospital of Yulin, Yulin, Guangxi, China

  ⨯
• Qianxi Chen ,

  Roles Writing – review & editing

  * E-mail: wonderfulqx@163.com (QXC), ylsymgy@163.com (GYM)

  Affiliation School of Pharmacy, Guangxi Medical University, Nanning, Guangxi, China

  ⨯
• Guangyi Meng

  Roles Writing – review & editing

  * E-mail: wonderfulqx@163.com (QXC), ylsymgy@163.com (GYM)

  Affiliation Department of Pharmacy, The First People’s Hospital of Yulin, Yulin, Guangxi, China

  https://orcid.org/0009-0007-3240-5191

  ⨯